Can Yeast Be The Future Of Large Scale And Efficient Subunit Vaccine Manufacturing?
By Lisa Yu and Devarshi Kapadia
![GettyImages-1307578388-Pichia pastoris yeast GettyImages-1307578388-Pichia pastoris yeast](https://vertassets.blob.core.windows.net/image/c2ac2ce0/c2ac2ce0-c329-424b-9eb0-f390c3bdf2a3/375_250-gettyimages_1307578388_pichia_pastoris_yeast.jpg)
Vaccines have been developed at record breaking speeds to fight the COVID-19 pandemic and are already saving lives1. At the time of writing, over 2.55 billion COVID-19 vaccine2 doses have been administered globally and are paving the way to a return to a "new normal." However, there is still a pressing need to develop more vaccine options to further increase global access, and prepare for future infectious disease challenges. To aid in the manufacturing of new vaccines, Pichia pastoris yeast, a promising protein expression system, could be the perfect solution.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
This website uses cookies to ensure you get the best experience on our website. Learn more